Updated First-line Osimertinib in Asian patients with Advanced EGFR-mutated Lung Cancer

被引：0
|
作者：
Tan, W. L. [1 ]
Tan, S. H. [1 ]
Tan, D. S. W. [1 ]
Lai, G. G. Y. [1 ]
Ang, M. -K. [1 ]
Jain, A. [1 ]
Kanesvaran, R. [1 ]
Rajasekaran, T. [1 ]
Saw, S. P. L. [1 ]
Teh, Y. L. [1 ]
Chan, J. [1 ]
Ng, Q. S. [1 ]
Lim, D. W. -T. [1 ]
机构：
[1] Natl Canc Ctr Singapore, Singapore, Singapore
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
EGFR-mutated NSCLC; First-line Osimertinib; Asian patients;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP12.01-31
引用
收藏
页码：S652 / S653
页数：2
相关论文
共 50 条
  • [41] Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLC
    Saw, Stephanie Pei Li
    Low, Yi Fen
    Lai, Gillianne
    Chan, Landon
    Wong, Wesley K. Y.
    Tsui, Giselle
    Chen, Olivia
    Seet, Amanda Oon Lim
    Tan, Wei Chong
    Tan, Aaron C.
    Chan, Johan W. K.
    Teh, Yi Lin
    Tan, Wan Ling
    Ng, Quan Sing
    Ang, Mei-Kim
    Kanesvaran, Ravindran
    Lim, Darren Wan-Teck
    Tan, Daniel Shao-Weng
    Mok, Tony S. K.
    Li, Molly Sc
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [42] Osimertinib or EGFR-TKIs/chemotherapy in patients with EGFR-mutated advanced nonsmall cell lung cancer A meta-analysis
    Huang, Lei
    Huang, Hao
    Zhou, Xiao-Ping
    Liu, Jin-Feng
    Li, Chun-Rong
    Fang, Min
    Wu, Jun-Rong
    MEDICINE, 2019, 98 (43)
  • [43] First-line treatments in EGFR-mutated advanced non-small cell lung cancer: A network meta-analysis
    Zhang, Hongwei
    Chen, Jun
    Liu, Tingting
    Dang, Jun
    Li, Guang
    PLOS ONE, 2019, 14 (10):
  • [44] The patient outcomes with EGFR-mutated advanced non-small-cell lung cancer receiving aumolertinib as first-line treatment
    Li, Jisheng
    Zhao, Wen
    Li, Hongxin
    Xuan, Tiantian
    Wang, Chengjun
    Zhang, Rongyu
    Yang, Chuang
    Wang, Jian
    Yi, Cuihua
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [45] Adjuvant Osimertinib Improves Overall Survival in EGFR-Mutated Lung Cancer
    Kim, Edward S.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (07) : 370 - 370
  • [46] Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLC
    Vergnenegre, Alain
    Massuti, Bartomeu
    de Marinis, Filippo
    Carcereny, Enric
    Felip, Enriqueta
    Do, Pascal
    Miguel Sanchez, Jose
    Paz-Arez, Luis
    Chouaid, Christos
    Rosell, Rafael
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (06) : 801 - 807
  • [47] First-line treatment of EGFR-mutated nonsmall cell lung cancer: critical review on study methodology
    Sebastian, Martin
    Schmittel, Alexander
    Reck, Martin
    EUROPEAN RESPIRATORY REVIEW, 2014, 23 (131): : 92 - 105
  • [48] First-line therapy based on kinase inhibitors and antibodies prevents resistance in EGFR-mutated lung cancer
    Marrocco, Ilaria
    Haga, Yuya
    Yarden, Yosef
    CANCER RESEARCH, 2022, 82 (12)
  • [49] CNS efficacy of osimertinib in EGFR-mutated advanced NSCLC
    Gourd, Elizabeth
    LANCET ONCOLOGY, 2018, 19 (10): : E516 - E516
  • [50] Osimertinib in untreated EGFR-mutated advanced lung adenocarcinoma: real world data
    Almusarhed, Manar
    Rehman, Faisal
    Chen, Ryan
    Ahmed, Samreen
    LUNG CANCER, 2023, 178 : S33 - S33
12345